CBG and Anxiety: What the First Human Clinical Trial Tells Us in 2026

CBG anxiety research has graduated from anecdote to peer-reviewed data, and the implications for the cannabinoid market are starting to come into focus. Cannabigerol — the so-called "mother cannabinoid" because most other cannabinoids in the plant biosynthesize from it — has spent most of the last decade as a niche ingredient in tinctures, gummies, and hemp-derived isolates. In 2024, that changed: the first human clinical trial on CBG's effects on stress and mood was published. In 2026, follow-up reviews and trials are pushing the research forward, and brands are taking notice.

Inside the Washington State University Trial

The pivotal study came out of Washington State University's psychology department, led by Dr. Carrie Cuttler. Published in Scientific Reports in July 2024, the double-blind, placebo-controlled crossover field trial gave 34 participants 20 mg of hemp-derived CBG or a placebo, then measured self-reported anxiety, stress, mood, and cognitive performance at multiple timepoints.

The results were notable for two reasons. First, participants reported significantly lower anxiety at 20, 45, and 60 minutes after taking CBG compared with placebo — a clean dose-response curve in a small but rigorously designed trial. Second, CBG did not produce the cognitive or motor impairments that researchers see with THC. In fact, the CBG group showed enhanced verbal memory recall, suggesting the compound is doing something distinct from sedation.

For a cannabinoid that, at the time of the study, was sold mostly on the strength of YouTube wellness reviews, this was the first piece of clinical evidence that CBG actually does something measurable on the kind of self-report scales clinicians use to assess anxiety.

Why CBG Hits Different from THC and CBD

To understand why these results sparked interest in 2026, it helps to look at where CBG sits in the cannabinoid landscape.

CBG is non-intoxicating. Unlike THC, it does not bind strongly to CB1 receptors in the brain, which is why participants in the WSU trial did not feel "high" — and why CBG products are legal and widely available under the 2018 Farm Bill's hemp framework as long as delta-9 THC stays below 0.3%.

CBG is rare in mature cannabis flower. Most cultivated cannabis converts CBGA (the acidic precursor) into THCA or CBDA as the plant matures. By the time most flower is harvested, CBG content has dropped well below 1%. Producers who want CBG-rich material either harvest early, use specially bred high-CBG varieties, or extract from purpose-grown hemp.

CBG appears to act through different mechanisms than CBD. Preclinical research suggests CBG interacts with the endocannabinoid system through alpha-2 adrenergic receptors and 5-HT1A serotonin receptors — pathways implicated in stress regulation, but distinct from the indirect modulation CBD is known for.

That mechanistic difference is part of why the 2024 WSU trial mattered. It suggested CBG might fill a niche neither THC nor CBD has cleanly occupied: real, measurable anxiolytic effects without intoxication and, importantly, without the THC-style cognitive trade-offs that have made some patients hesitant to use cannabis during the workday.

What 2026 Research Adds

In 2026, the field is moving from a single signal study to a broader evidence base. A new review published in Phytomedicine Plus in early 2026 synthesized emerging pharmacological data on CBG, covering anti-inflammatory, neuroprotective, and antimicrobial pathways alongside the anxiety findings. The authors are clear-eyed about the state of evidence: most CBG research is still preclinical or based on small samples, and replication is needed before clinical guidelines can shift.

Cuttler's WSU team is reportedly designing a larger follow-up trial that will include physiological measures — heart rate variability, blood pressure, cortisol — alongside the self-report scales used in the original study. Cuttler has also signaled interest in testing CBG in menopausal women, a population for whom anxiety, sleep disruption, and mood symptoms often overlap and existing pharmacological options have meaningful side effects.

Industry-side, hemp companies have leaned into the story aggressively. CBG isolate prices have ticked up across major suppliers as more brands launch dedicated CBG SKUs. In 2026, dosing has begun to standardize around 20 mg as a minimum effective dose for stress and mood, mirroring the WSU protocol — a reasonable move, but one that runs ahead of where the formal evidence base actually sits.

How CBG Compares with CBD for Stress and Anxiety

The natural follow-up question is whether CBG actually outperforms CBD, the cannabinoid most consumers already associate with stress relief. The honest answer in 2026 is: we don't know yet from head-to-head trials.

The WSU CBG trial used 20 mg doses; most CBD anxiety research uses 25 to 600 mg, with effective ranges spread across that band depending on the condition. The trials are not directly comparable. Anecdotally, users on CBG report a quicker, lighter, more "focus-forward" feel compared with CBD's slower, more sedating profile — but anecdote is not science, and placebo effects on subjective stress measures are notoriously strong.

What the WSU data does suggest is that CBG likely won't replace CBD; rather, it will sit alongside it as another tool. Many 2026 product launches are pairing the two, marketing 1:1 or 2:1 CBD-to-CBG ratios for "balanced calm." The pharmacological rationale for those ratios is thin, but consumer demand for choice is real.

Buying CBG in 2026: What to Look For

For consumers interested in trying CBG, the buyer's market in 2026 is more developed than it was even 18 months ago — but it is still uneven. A few practical points:

Look for brands that publish a current Certificate of Analysis (COA) showing actual CBG content, not just total cannabinoid content. Some products marketed as "CBG-rich" contain only trace CBG with most of the cannabinoid load coming from CBD.

Check the THC level. Hemp-derived CBG products should have less than 0.3% delta-9 THC, but minor cannabinoid contamination has been a recurring quality issue. A clean COA from a third-party lab is the bare minimum.

Match the dose to the evidence. The 20 mg used in the WSU trial is a reasonable benchmark for stress and mood. Lower doses may have effects, but the published data does not support claims at sub-clinical doses.

Be skeptical of disease-modifying claims. CBG has shown promise in preclinical research for inflammatory bowel disease, glaucoma, and certain cancers, but no human clinical trials have established efficacy for those indications. Marketing language that crosses the line into therapeutic claims should be a red flag.

What This Means for Cannabis Wellness

CBG anxiety research is part of a broader 2026 shift in cannabis wellness: away from a THC-centric "more is better" model and toward minor cannabinoids matched to specific outcomes. Whether the WSU findings hold up in larger replication trials will determine whether CBG becomes a durable category or a passing wellness fad. The next 12 to 24 months of data will tell us more.

For now, the most defensible read is that CBG has earned a seat at the table. It is no longer a fringe cannabinoid — it is an active research target, a growing product category, and, for some users, a genuinely useful alternative to existing options for daily stress management.

Key Takeaways

• The first human clinical trial of CBG, published in Scientific Reports in 2024, found that 20 mg of CBG significantly reduced self-reported anxiety at 20, 45, and 60 minutes versus placebo, without intoxication or cognitive impairment.
• A 2026 Phytomedicine Plus review synthesizes growing pharmacological data on CBG and emphasizes the need for larger replication studies.
• CBG appears to act through alpha-2 adrenergic and 5-HT1A serotonin pathways, distinct from THC's CB1 binding and CBD's indirect modulation.
• Buyers should look for COA-verified CBG content, less than 0.3% delta-9 THC, and 20 mg doses consistent with the published clinical research.
• CBG is unlikely to replace CBD; instead, both cannabinoids look set to coexist as differentiated tools for stress, mood, and sleep support in the 2026 wellness market.

Explore cannabis news, find dispensaries, and join the community at Budpedia.